Empatica Inc

Empatica Inc is an MIT spin-off specializing in medical-grade wearable technology for remote patient monitoring and clinical research. The company develops FDA-cleared devices, software platforms, and AI algorithms that collect continuous health data from patients in real-world settings. With over 100,000 devices deployed globally across 160+ countries, Empatica serves pharmaceutical companies, research institutions, and healthcare providers.

The company's flagship offerings include the Empatica Health Monitoring Platform for clinical trials and EpiMonitor for epilepsy monitoring. Empatica has achieved seven FDA clearances and offers over 300 digital measures from a single wearable device. Their technology has been referenced in more than 12,000 research papers and is used by over half of the top 20 pharmaceutical companies.

Recent developments include the acquisition of PKG Health to expand Parkinson's disease monitoring capabilities and the launch of EmbraceMini, described as the world's smallest actigraphy wearable for clinical trials. The company maintains offices in Boston, Milan, and Seoul with a team of over 100 employees.

Organizations should consider Empatica when regulatory compliance and data quality are paramount for clinical research or patient monitoring programs. The company's track record with FDA clearances and validation across hundreds of clinical studies provides confidence for pharmaceutical trials and academic research requiring defensible digital endpoints.

Empatica excels in scenarios requiring passive, continuous monitoring at scale, particularly for neurological conditions. Buyers can expect a comprehensive platform approach with medical-grade hardware, validated algorithms, and supporting software infrastructure, backed by ongoing development and strong institutional partnerships.

Empatica operates exclusively in healthcare with deep specialization in neurological conditions, particularly epilepsy and Parkinson's disease. The company's FDA-cleared devices and platform are purpose-built for clinical trials and patient monitoring, with specific expertise in seizure detection, movement disorder assessment, and sleep analysis.

Their healthcare focus extends to pharmaceutical development partnerships, supporting drug trials with validated digital biomarkers and endpoints. The recent BARDA partnership for COVID-19 detection and ongoing work with NASA on physiological monitoring demonstrate the company's commitment to advancing medical-grade wearable technology across various healthcare applications.

Ideal clients include pharmaceutical companies running multi-site clinical trials, academic medical centers conducting neurological research, and healthcare systems implementing specialized epilepsy monitoring programs. Organizations with established research protocols, regulatory requirements, and the scale to deploy 50+ devices will find the platform most valuable.